Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-B: Surovatamig in relapsed or refractory B-cell non-Hodgkin lymphoma
CTR20250894Phase 2Active
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of surovatamig in mature B-cell lymphoma, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Started May 2025; status: active.
02
Drugs
surovatamig
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20250894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250894.